Facility Design and Engineering

The facility has dedicated manufacturing and packaging for oral solid dosage forms, liquids, creams, and ointments.

The company will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing capabilities.

The company will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France.

Manufacturers are adapting with virtual work, remote monitoring, and re-evaluation of facility design to ensure worker safety.

The company is planning on adding up to 1.5 million sq. ft. of cGMP distribution space for COVID-19 shipments.

The investment will increase production lines for bulk drug substance and will add a fill/finish production line to the site.

Siemens and Exyte partner for fast-track construction of modular, automated, digitalized biopharmaceutical facilities.

The center will offer expertise in fill-finish optimization and analytical testing.

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.

The new facility in County Mayo includes an ISO class 7 cleanroom for the manufacturing of single-use systems.

The 60,000-ft2 facility will work in conjunction with the company’s Kakegawa, Japan, clinical supply facility to serve local and global biotech and pharmaceutical companies.

US manufacturers focus on preparing capacity while vaccines and treatments for COVID-19 are being developed and tested.

Evonik opened a new facility for GMP manufacturing of bioresorbable polymers and excipients for pharmaceutical and medical applications in Birmingham, AL.

The company will invest $180 million to construct a new 290,000-ft2 facility in Plainville, MA.

The center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020.

Remote, machine health monitoring services reduce the need for on-site visits.

The goal of the collaboration is to manufacture up to one billion does per year of mRNA-1273, Moderna’s vaccine against the novel coronavirus.

The technology center is dedicated to developing greener, safer chemistries for manufacturing pharmaceutical raw materials and intermediates.

ISPE’s Facility of the Year Awards for 2020 go to bio/pharma companies in eight award categories, including two winners in the new Social Impact category.

Risk levels should be considered when designing containment for pharmaceutical tableting equipment to enhance operator safety.

Whether refitting existing spaces or building new, the need for quick build times, flexibility, and production efficiency is driving trends in bio/pharma facility construction.

Thermo Fisher is focused on investing to expand three specific areas of demand: biologics, cell and gene therapy, and drug product development and commercial capabilities.

Technologies and methods for new and refurbished manufacturing facility construction expand capacity for new modalities and to ease shortages.

Through the agreement, Bora will obtain ownership of the entire Mississauga site, including all facilities, under the proper regulatory clearances.

The growing interest in developing cell and gene therapies has prompted industry investment to grow manufacturing capacity.

The last year has seen intense investment activity into raising cell and gene therapy manufacturing capacity.

Energy and water waste can be improved with new technologies, and sustainability can be considered in the design of new facilities.

The expansion gives the company diversified capacity running cell production lines featuring Sartorius-brand 2000-L disposable bioreactors and now GE-brand 2000-L single-use bioreactors.

The 135,000 square foot facility will be constructed over 18 months and is expected to be operational in 2021.

The new facility includes six classified environment rooms with space to expand.